7
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Racial and Ethnic Disparities in COVID-19 Incidence by Age, Sex, and Period Among Persons Aged <25 Years — 16 U.S. Jurisdictions, January 1–December 31, 2020

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The COVID-19 pandemic has disproportionately affected racial and ethnic minority groups in the United States. Whereas racial and ethnic disparities in severe COVID-19–associated outcomes, including mortality, have been documented ( 1 – 3 ), less is known about population-based disparities in infection with SARS-CoV-2, the virus that causes COVID-19. In addition, although persons aged <30 years account for approximately one third of reported infections, § there is limited information on racial and ethnic disparities in infection among young persons over time and by sex and age. Based on 689,672 U.S. COVID-19 cases reported to CDC’s case-based surveillance system by jurisdictional health departments, racial and ethnic disparities in COVID-19 incidence among persons aged <25 years in 16 U.S. jurisdictions ¶ were described by age group and sex and across three periods during January 1–December 31, 2020. During January–April, COVID-19 incidence was substantially higher among most racial and ethnic minority groups compared with that among non-Hispanic White (White) persons (rate ratio [RR] range = 1.09–4.62). During May–August, the RR increased from 2.49 to 4.57 among non-Hispanic Native Hawaiian and Pacific Islander (NH/PI) persons but decreased among other racial and ethnic minority groups (RR range = 0.52–2.82). Decreases in disparities were observed during September–December (RR range = 0.37–1.69); these decreases were largely because of a greater increase in incidence among White persons, rather than a decline in incidence among racial and ethnic minority groups. NH/PI, non-Hispanic American Indian or Alaska Native (AI/AN), and Hispanic or Latino (Hispanic) persons experienced the largest persistent disparities over the entire period. Ensuring equitable and timely access to preventive measures, including testing, safe work and education settings, and vaccination when eligible is important to address racial/ethnic disparities. Population-based COVID-19 incidence (cases per 100,000 persons) by race and ethnicity, sex, and age was calculated for January 1–December 31, 2020, overall, and for three approximately equal 4-month periods (January 1–April 30, May 1–August 31, and September 1–December 31) using COVID-19 cases reported to CDC’s case-based surveillance system** by jurisdictional health departments. Incompleteness of race and ethnicity data is a widespread challenge in analyses of COVID-19 disparities. †† To minimize the impact of missing data, jurisdictions selected for analyses reported ≥30% of the total number of jurisdictional aggregate cases §§ to CDC and had ≥70% of race and ethnicity information complete among cases reported during January 1–December 31, 2020. Fifteen U.S. states and the District of Columbia were included, with a total of 689,672 cases among persons aged <25 years with information on race and ethnicity and sex. ¶¶ Population denominators were obtained from the 2019 U.S. Census Bureau’s Annual County Resident Population Estimates by Age, Sex, Race, and Hispanic Origin.*** Seven racial and ethnic categories (AI/AN, non-Hispanic Asian [Asian], non-Hispanic Black or African-American [Black], NH/PI, White, Hispanic, and non-Hispanic multiple race [multiracial]) and five age categories (0–4, 5–9, 10–14, 15–19, and 20–24 years) were examined. RRs with 95% confidence intervals (CIs) comparing rates by race and ethnicity (combined), age, and/or sex overall and for each period were calculated. Statistical analyses were conducted using SAS software (version 9.4; SAS Institute). Rate ratios with 95% CIs excluding 1.0 were considered to be statistically significant. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. ††† The sample of 689,672 cases included 15,068 (2%) cases identified during January–April; 177,778 (26%) during May–August and 496,826 (72%) during September–December (Table 1). During January–April, COVID-19 incidence ranged from 35 cases per 100,000 among White persons to 163 per 100,000 among AI/AN persons. Compared with White persons, rates were higher among AI/AN (RR = 4.62), Hispanic (RR = 3.87), NH/PI (RR = 2.49), Black (RR = 2.46), and Asian persons (RR = 1.53) and were approximately equal among multiracial persons (RR = 1.09). TABLE 1 COVID–19 incidence* and rate ratios, by race/ethnicity, sex, and age group among persons aged <25 years across three periods — 16 U.S. jurisdictions, † January 1–December 31, 2020 Date/Characteristic No. of cases Cases per 100,000 population (95% CI) RR (95% CI) January 1–April 30, 2020 All 15,068 63 (62–64) — Sex Male 6,884 57 (55–58) 0.80 (0.78–0.83) Female 8,184 70 (69–72) Ref Race/Ethnicity AI/AN, non-Hispanic 536 163 (150–177) 4.62 (4.22–5.05) Asian, non-Hispanic 498 54 (49–59) 1.53 (1.39–1.67) Black, non-Hispanic 2,461 87 (83–90) 2.46 (2.34–2.58) NH/PI, non-Hispanic 73 88 (70–111) 2.49 (1.98–3.14) White, non-Hispanic 4,947 35 (34–36) Ref Hispanic/Latino 6,129 137 (133–140) 3.87 (3.73–4.02) Multiple, non-Hispanic 424 38 (35–42) 1.09 (0.98–1.20) Age group (yrs) 0–4 956 21 (20–23) 1.28 (1.17–1.41) 5–9 772 17 (16–18) Ref 10–14 1,184 25 (23–26) 1.49 (1.36–1.63) 15–19 3,267 67 (65–70) 4.03 (3.72–4.36) 20–24 8,889 175 (171–178) 10.47 (9.72–11.26) May 1–August 31, 2020 All 177,778 747 (744–751) — Sex Male 84,270 693 (688–698) 0.86 (0.85–0.87) Female 93,508 804 (799–809) Ref Race/Ethnicity AI/AN, non-Hispanic 3,245 986 (952–1,020) 1.86 (1.80–1.93) Asian, non-Hispanic 3,781 409 (396–422) 0.77 (0.75–0.80) Black, non-Hispanic 24,501 862 (852–873) 1.63 (1.61–1.65) NH/PI, non-Hispanic 2,007 2,418 (2,314–2,526) 4.57 (4.37–4.77) White, non-Hispanic 74,259 530 (526–533) Ref Hispanic/Latino 66,938 1,493 (1,481–1,504) 2.82 (2.79–2.85) Multiple, non-Hispanic 3,047 275 (266–285) 0.52 (0.50–0.54) Age group (yrs) 0–4 14,017 314 (309–319) 1.01 (0.98–1.03) 5–9 14,406 312 (307–317) Ref 10–14 20,490 430 (424–436) 1.38 (1.35–1.41) 15–19 50,210 1,034 (1,025–1,043) 3.32 (3.26–3.38) 20–24 78,655 1,547 (1,536–1,557) 4.96 (4.88–5.05) September 1–December 31, 2020 All 496,826 2,088 (2,082–2,094) — Sex Male 236,237 1,943 (1,935–1,951) 0.87 (0.86–0.87) Female 260,589 2,240 (2,231–2,248) Ref Race/Ethnicity AI/AN, non-Hispanic 11,870 3,605 (3,541–3,671) 1.62 (1.59–1.65) Asian, non-Hispanic 11,680 1,263 (1,240–1,286) 0.57 (0.56–0.58) Black, non-Hispanic 32,200 1,133 (1,121–1,146) 0.51 (0.50–0.52) NH/PI, non-Hispanic 3,119 3,757 (3,628–3,891) 1.69 (1.63–1.75) White, non-Hispanic 311,591 2,222 (2,214–2,230) Ref Hispanic/Latino 117,305 2,616 (2,601–2,631) 1.18 (1.17–1.19) Multiple, non-Hispanic 9,061 819 (803–836) 0.37 (0.36–0.38) Age group (yrs) 0–4 33,595 752 (744–760) 0.71 (0.70–0.72) 5–9 48,824 1,056 (1,047–1,066) Ref 10–14 76,922 1,615 (1,604–1,627) 1.53 (1.51–1.55) 15–19 149,660 3,083 (3,067–3,098) 2.92 (2.89–2.95) 20–24 187,825 3,693 (3,677–3,710) 3.50 (3.46–3.53) January 1–December 31, 2020 All 689,672 2,899 (2,892–2,906) — Sex Male 327,391 2,693 (2,684–2,702) 0.86 (0.86–0.87) Female 362,281 3,114 (3,104–3,124) Ref Race/Ethnicity AI/AN, non-Hispanic 15,651 4,754 (4,680–4,829) 1.71 (1.68–1.73) Asian, non-Hispanic 15,959 1,725 (1,699–1,752) 0.62 (0.61–0.63) Black, non-Hispanic 59,162 2,083 (2,066–2,099) 0.75 (0.74–0.75) NH/PI, non-Hispanic 5,199 6,263 (6,095–6,436) 2.25 (2.19–2.31) White, non-Hispanic 390,797 2,787 (2,778–2,795) Ref Hispanic/Latino 190,372 4,245 (4,226–4,264) 1.52 (1.52–1.53) Multiple, non-Hispanic 12,532 1,133 (1,113–1,153) 0.41 (0.40–0.41) Age group (yrs) 0–4 48,568 1,087 (1,078–1,097) 0.79 (0.78–0.79) 5–9 64,002 1,385 (1,374–1,395) Ref 10–14 98,596 2,070 (2,057–2,083) 1.50 (1.48–1.51) 15–19 203,137 4,184 (4,166–4,202) 3.02 (2.99–3.05) 20–24 275,369 5,415 (5,394–5,435) 3.91 (3.88–3.94) Abbreviations: AI/AN = American Indian or Alaska Native; CI = confidence interval; NH/PI = Native Hawaiian and Pacific Islander; Ref = referent group; RR = rate ratio. * Rates for each period and for the full period were calculated using the following equation: (cases/population) x 100,000 persons. COVID–19 cases were identified using CDC’s Data Collation and Integration for Public Health Event Response system (https://data.cdc.gov/browse?tags=covid-19 [accessed January 27, 2021]). Case surveillance data were received directly from two jurisdictional health departments (Hawaii State Department of Health and New Mexico Department of Health) for all racial/ethnic groups to allow for separate reporting of NH/PI persons. Population estimates were provided by the 2019 U.S. Census Bureau’s Annual County Resident Population Estimates by Age, Sex, Race, and Hispanic Origin (https://www.census.gov/programs-surveys/popest/technical-documentation/file-layouts.html [accessed August 20, 2020]). 2019 population estimates in the 16 selected jurisdictions were as follows: persons aged <25 years: all (23,792,864), males (12,157,933), females (11,634,931), non-Hispanic AI/AN (329,235), non-Hispanic Asian (925,072), non-Hispanic Black or African-American (2,840,777), non-Hispanic NH/PI (83,012), non-Hispanic White (14,024,304), Hispanic or Latino (4,484,434), and non-Hispanic persons of multiple races (1,106,030); and persons aged 0–4 years (4,467,369), 5–9 years (4,622,261), 10–14 years (4,762,433), 15–19 years (4,855,127), and 20–24 years (5,085,674). No measures were calculated for non-Hispanic persons of other races with COVID-19 (n = 19,627) because of lack of population denominator information from U.S. Census Bureau. † Arkansas, District of Columbia, Florida, Hawaii, Kansas, Kentucky, Maine, Massachusetts, Michigan, Minnesota, New Mexico, Oklahoma, Oregon, Utah, Vermont, and Wisconsin. From January–April to May–August, COVID-19 incidence increased among all racial and ethnic groups, ranging from 275 per 100,000 among multiracial persons to 2,418 per 100,000 among NH/PI persons. The largest relative increase occurred among NH/PI persons, with incidence increasing 26-fold, from 88 to 2,418 per 100,000. Rate ratios increased among NH/PI persons but decreased among other racial and ethnic minority groups. During May–August, compared with that among White persons, incidence remained higher among NH/PI (RR = 4.57), Hispanic (RR = 2.82), AI/AN (RR = 1.86), and Black persons (RR = 1.63), but was lower among Asian (RR = 0.77) and multiracial persons (RR = 0.52). From May–August to September–December, COVID-19 incidence increased among all racial and ethnic groups. The largest relative increase occurred among White persons, with incidence increasing approximately 320%, from 530 to 2,222 cases per 100,000 from May–August to September–December. Disparities decreased among all racial and ethnic minority groups. During September–December, compared with that among White persons, incidence remained higher among NH/PI (RR = 1.69), AI/AN (RR = 1.62), and Hispanic persons (RR = 1.18), but was lower among Asian (RR = 0.57), Black (RR = 0.51), and multiracial persons (RR = 0.37). Incidence was higher among females than among males during all of 2020 and across periods. Incidence also tended to be lowest among younger children across periods. Lowest incidence was observed among children aged 5–9 years during January–April, those aged 0–9 years during May–August, and those aged 0–4 years during September–December. During January–December, overall, the highest COVID-19 incidence relative to that among White persons was among NH/PI persons of most age groups, with the largest differences among those aged 0–4 (RR = 4.03) and 5–9 years (RR = 3.21) (Figure) (Supplementary Table, https://stacks.cdc.gov/view/cdc/103733). During January–December, among persons aged ≤14 years, incidence relative to White persons was initially higher among Black and Asian persons and persistently higher among NH/PI, AI/AN, and Hispanic persons; among persons aged 15–24 years, incidence relative to White persons was initially higher among Black, Asian, and multiracial persons, and persistently higher among NH/PI, AI/AN, and Hispanic persons. Overall, during January–December, differences compared with White persons among AI/AN, NH/PI, and Hispanic persons were larger in persons aged ≤14 years than among those aged 15–24 years. Racial and ethnic disparities were similar in magnitude and direction for both females and males across age groups (Table 2). FIGURE Rate ratios* comparing COVID-19 incidence † among racial and ethnic minority persons to COVID-19 incidence among non-Hispanic White persons, among persons aged <25 years, by age group in three periods — 16 U.S. jurisdictions, § January 1–December 31, 2020 Abbreviations: AI/AN=American Indian or Alaska Native; NH/PI=Native Hawaiian and Pacific Islander; ref = referent group. * Rate ratios were calculated during each period and overall. Data used to generate this figure are included in the Supplementary Table, https://stacks.cdc.gov/view/cdc/103733. Rate ratios are not available in situations where data were suppressed because of <20 cases being reported for a given race/ethnicity and age group during a period. During January 1–April 30, 2020, <20 cases were reported for non-Hispanic NH/PI persons aged 0–4, 5–9, 10–14, and 15–19 years. Rate ratios were similar and thus corresponding rate ratio symbols overlap in the figure for the following categories: AI/AN persons aged 15–19 and 20–24 years during May 1–August 31 and September 1–December 31; Black persons aged 5–9 years during January 1–April 30 and May 1–August 31; and NH/PI persons aged 20–24 years during January 1–April 30 and September 1–December 31. † Rates for each period and for the full period were calculated using the following equation: (cases/population) x 100,000 persons. COVID-19 cases were identified using CDC’s Data Collation and Integration for Public Health Event Response system (https://data.cdc.gov/browse?tags=covid-19 [accessed January 27, 2021]). Case surveillance data were received directly from two jurisdictional health departments (Hawaii State Department of Health and New Mexico Department of Health) for all racial/ethnic groups to allow for separate reporting of NH/PI persons. Population estimates were provided by the 2019 U.S. Census Bureau’s Annual County Resident Population Estimates by Age, Sex, Race, and Hispanic Origin (https://www.census.gov/programs-surveys/popest/technical-documentation/file-layouts.html [accessed August 20, 2020]). § Arkansas, District of Columbia, Florida, Hawaii, Kansas, Kentucky, Maine, Massachusetts, Michigan, Minnesota, New Mexico, Oklahoma, Oregon, Utah, Vermont, and Wisconsin. The figure is a scatter plot showing the rate ratios comparing COVID-19 incidence among racial and ethnic minority persons to COVID-19 incidence among non-Hispanic White persons, among persons aged <25 years, by age group in three periods, in 16 U.S. jurisdictions, during January 1–December 31, 2020. TABLE 2 Sex-specific COVID-19 incidence* and rate ratios among persons aged <25 years, by age group, sex, and race/ethnicity — 16 U.S. jurisdictions, † January 1–December 31, 2020 Age group, race/ethnicity Sex Female Male No. of cases Cases per 100,000 population (95% CI) Rate ratio (95% CI) No. of cases Cases per 100,000 population (95% CI) Rate ratio (95% CI) 0–4 yrs All 23,272 1,067 (1,053–1,081) — 25,296 1,107 (1,093–1,120) — AI/AN, non-Hispanic 658 2,247 (2,082–2,425) 2.69 (2.49–2.91) 677 2,208 (2,048–2,381) 2.54 (2.35–2.75) Asian, non-Hispanic 642 858 (794–927) 1.03 (0.95–1.11) 721 913 (849–982) 1.05 (0.98–1.13) Black, non-Hispanic 2,541 940 (904–977) 1.13 (1.08–1.18) 2,844 1,028 (991–1,067) 1.18 (1.14–1.23) NH/PI, non-Hispanic 266 3,576 (3,171–4,033) 4.28 (3.79–4.83) 258 3,306 (2,926–3,735) 3.81 (3.37–4.31) White, non-Hispanic 10,391 835 (820–852) Ref 11,382 868 (852–884) Ref Hispanic/Latino 8,299 1,901 (1,861–1,943) 2.28 (2.21–2.34) 8,889 1,951 (1,910–1,992) 2.25 (2.19–2.31) Multiple, non-Hispanic 475 399 (365–436) 0.48 (0.44–0.52) 525 420 (386–458) 0.48 (0.44–0.53) 5–9 yrs All 31,333 1,389 (1,374–1,404) — 32,669 1,381 (1,366–1,396) — AI/AN, non-Hispanic 917 2,901 (2,719–3,095) 2.40 (2.24–2.56) 941 2,861 (2,684–3,050) 2.39 (2.24–2.56) Asian, non-Hispanic 741 904 (841–971) 0.75 (0.69–0.80) 890 1,048 (981–1,119) 0.88 (0.82–0.94) Black, non-Hispanic 3,019 1,081 (1,043–1,120) 0.89 (0.86–0.93) 3,155 1,096 (1,058–1,135) 0.92 (0.88–0.95) NH/PI, non-Hispanic 287 3,676 (3,275–4,127) 3.04 (2.70–3.42) 326 4,040 (3,624–4,503) 3.38 (3.03–3.77) White, non-Hispanic 15,609 1,210 (1,191–1,229) Ref 16,280 1,195 (1,177–1,214) Ref Hispanic/Latino 10,174 2,271 (2,227–2,315) 1.88 (1.83–1.92) 10,564 2,264 (2,221–2,308) 1.89 (1.85–1.94) Multiple, non-Hispanic 586 501 (462–543) 0.41 (0.38–0.45) 513 414 (380–452) 0.35 (0.32–0.38) 10–14 yrs All 49,235 2,112 (2,094–2,131) — 49,361 2,030 (2,012–2,048) — AI/AN, non-Hispanic 1,477 4,461 (4,239–4,694) 2.31 (2.19–2.44) 1,520 4,492 (4,272–4,723) 2.42 (2.30–2.55) Asian, non-Hispanic 949 1,089 (1,022–1,160) 0.56 (0.53–0.60) 1,066 1,210 (1,140–1,285) 0.65 (0.61–0.69) Black, non-Hispanic 4,192 1,510 (1,465–1,556) 0.78 (0.76–0.81) 4,042 1,416 (1,373–1,461) 0.76 (0.74–0.79) NH/PI, non-Hispanic 424 4,803 (4,367–5,283) 2.49 (2.26–2.74) 445 4,779 (4,355–5,245) 2.58 (2.35–2.83) White, non-Hispanic 26,147 1,930 (1,907–1,954) Ref 26,360 1,853 (1,831–1,876) Ref Hispanic/Latino 15,128 3,335 (3,282–3,389) 1.73 (1.69–1.76) 15,020 3,175 (3,125–3,226) 1.71 (1.68–1.75) Multiple, non-Hispanic 918 794 (744–847) 0.41 (0.39–0.44) 908 760 (712–811) 0.41 (0.38–0.44) 15–19 yrs All 109,350 4,601 (4,574–4,628) — 93,787 3,784 (3,760–3,808) — AI/AN, non-Hispanic 2,432 7,218 (6,937–7,511) 1.55 (1.49–1.61) 1,971 5,634 (5,391–5,889) 1.54 (1.47–1.61) Asian, non-Hispanic 2,133 2,181 (2,090–2,275) 0.47 (0.45–0.49) 1,960 2,065 (1,975–2,158) 0.56 (0.54–0.59) Black, non-Hispanic 8,056 2,915 (2,852–2,979) 0.63 (0.61–0.64) 7,774 2,715 (2,655–2,776) 0.74 (0.72–0.76) NH/PI, non-Hispanic 715 8,679 (8,066–9,339) 1.86 (1.73–2.01) 633 7,253 (6,709–7,840) 1.98 (1.83–2.14) White, non-Hispanic 66,431 4,655 (4,620–4,691) Ref 54,869 3,661 (3,630–3,691) Ref Hispanic/Latino 27,571 6,361 (6,286–6,436) 1.37 (1.35–1.39) 24,846 5,497 (5,430–5,566) 1.50 (1.48–1.52) Multiple, non-Hispanic 2,012 2,010 (1,924–2,100) 0.43 (0.41–0.45) 1,734 1,689 (1,612–1,771) 0.46 (0.44–0.48) 20–24 yrs All 149,091 5,987 (5,957–6,018) — 126,278 4,865 (4,839–4,892) — AI/AN, non-Hispanic 2,881 8,386 (8,086–8,698) 1.43 (1.38–1.48) 2,177 6,253 (5,995–6,521) 1.34 (1.29–1.40) Asian, non-Hispanic 3,558 2,997 (2,900–3,097) 0.51 (0.49–0.53) 3,299 2,805 (2,711–2,903) 0.60 (0.58–0.62) Black, non-Hispanic 12,708 4,316 (4,241–4,391) 0.74 (0.72–0.75) 10,831 3,534 (3,468–3,601) 0.76 (0.74–0.78) NH/PI, non-Hispanic 941 11,453 (10,744–12,209) 1.95 (1.83–2.08) 904 10,546 (9,880–11,256) 2.27 (2.12–2.42) White, non-Hispanic 89,490 5,867 (5,829–5,906) Ref 73,838 4,649 (4,615–4,682) Ref Hispanic/Latino 36,744 8,775 (8,685–8,865) 1.50 (1.48–1.51) 33,137 7,418 (7,339–7,499) 1.60 (1.58–1.62) Multiple, non-Hispanic 2,769 3,059 (2,947–3,175) 0.52 (0.50–0.54) 2,092 2,251 (2,156 –2,349) 0.48 (0.46–0.51) Abbreviations: AI/AN = American Indian or Alaska Native; CI = confidence interval; NH/PI = Native Hawaiian and Pacific Islander; Ref = referent group. * Rates for each period and for the full period were calculated using the following equation: (cases/population) x 100,000 persons. COVID-19 cases were identified using CDC’s Data Collation and Integration for Public Health Event Response system (https://data.cdc.gov/browse?tags=covid-19 [accessed January 27, 2021]). Case surveillance data were received directly from two jurisdictional health departments (Hawaii State Department of Health and New Mexico Department of Health) for all racial/ethnic groups to allow for separate reporting of NH/PI persons. Population estimates were provided by the 2019 U.S. Census Bureau’s Annual County Resident Population Estimates by Age, Sex, Race, and Hispanic Origin (https://www.census.gov/programs-surveys/popest/technical-documentation/file-layouts.html [accessed August 20, 2020]). † Arkansas, District of Columbia, Florida, Hawaii, Kansas, Kentucky, Maine, Massachusetts, Michigan, Minnesota, New Mexico, Oklahoma, Oregon, Utah, Vermont, and Wisconsin. Discussion Analysis of CDC’s case-based surveillance data in 16 U.S. jurisdictions during January–December 2020 indicates that racial and ethnic differences in COVID-19 incidence among persons aged <25 years changed over time. Disparities were substantial early in the pandemic among most racial and ethnic minority groups compared with White persons and then decreased over time, largely because of a greater increase in incidence among White persons. Among NH/PI persons, disparities increased from January–April to May–August and then decreased by September–December. The largest persistent disparities in COVID-19 incidence were among NH/PI, AI/AN, and Hispanic persons. Other studies have reported disproportionately higher percentages of COVID-19 cases among Hispanic, Black, Asian, and AI/AN children ( 4 , 5 ); however, no published studies to date have described national COVID-19 incidence among NH/PI children. Social determinants of health influence racial and ethnic disparities in case incidence. §§§ The large racial and ethnic COVID-19 disparities identified early in the pandemic in this analysis might reflect differential ability to participate in early mitigation measures, such as stay-at-home orders ( 6 ). Racial and ethnic minority groups are disproportionately represented in essential work settings, making it difficult for youths and parents to stay at home; a higher likelihood of living in a multigenerational household also increases the risk for household exposures to SARS-CoV-2. ¶¶¶ For example, NH/PI persons, a group with some of the largest persistent disparities in this analysis, most often reside in multigenerational homes compared with other racial and ethnic groups ( 7 ). Despite on average having lower income and educational attainment, NH/PI persons are often grouped in analyses with Asian persons ( 8 ), thereby obscuring disparities influenced by these social determinants of health. The decrease in racial and ethnic disparities observed over time was largely driven by a greater increase in COVID-19 incidence among White persons, rather than a decrease among racial and ethnic minority groups. This narrowing in differences should be considered in the context of geographic aspects of community spread over time and potential changes in access to or participation in mitigation measures or testing over time by race and ethnicity. For example, future studies could consider whether variations in state-mandated mitigation policies and other aspects of the policy environment led to the observed differential adherence in some mitigation measures by race/ethnicity ( 9 ). Further study of whether some testing strategies (e.g., repeat testing of students in some academic settings****) might have been differentially available by race and ethnicity over time is also needed. The findings in this report are subject to at least five limitations. First, reporting of detailed case data and race and ethnicity to CDC is incomplete. Although this analysis was restricted to 16 jurisdictions with more complete case and race and ethnicity information, 23% of cases from these jurisdictions were missing data on race and ethnicity. Differences in data completeness by race and ethnicity could lead to underestimation of disparities ( 10 ). Restriction to 16 jurisdictions also limits the generalizability of these findings, because they are based on only 23% of the national population of persons aged <25 years; in addition, disparities could vary at geographic subdivisions within states. Second, these data likely underestimate the incidence of COVID-19 among persons aged <25 years because individual-level cases reported to CDC represent a portion of jurisdictional aggregate cases and asymptomatic persons are less likely to be tested. Third, cases among racial and ethnic minority groups might be disproportionately underreported given disparities in access to testing, leading to underestimation of disparities. Fourth, potential differences in testing, reporting, and completeness of data by race and ethnicity over time call for caution in interpretation of the observed changes in racial and ethnic disparities in this report. Finally, racial and ethnic disparities in COVID-19 incidence (and changes over time) might not reflect disparities in severe outcomes ( 1 – 3 ). †††† During January 1–December 31, 2020, substantial racial and ethnic disparities in COVID-19 incidence, observed early in the pandemic among persons aged <25 years in 16 jurisdictions, decreased over time, driven largely by a greater increase in reporting of cases among White persons. The largest persistent disparities were among NH/PI, AI/AN, and Hispanic persons. Ensuring equitable and timely access to preventive measures, including testing, safe work and education settings and vaccination when eligible is important to address racial/ethnic disparities. §§§§ Summary What is already known about this topic? U.S. racial and ethnic minority groups have been disproportionately affected by COVID-19. What is added by this report? Racial and ethnic disparities in COVID-19 incidence among persons aged <25 years in 16 U.S. jurisdictions evolved during the pandemic. Disparities were substantial during January–April and generally decreased during May–December, largely because of a greater increase in incidence among White persons, rather than a decline among racial and ethnic minority groups. The largest persistent disparities involved Native Hawaiian and Pacific Islander, American Indian or Alaska Native, and Hispanic persons. What are the implications for public health practice? Ensuring equitable and timely access to preventive measures, including testing, safe work and education settings, and vaccination when eligible is important to address racial/ethnic disparities.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: found

          COVID-19 and Racial/Ethnic Disparities

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020

            Most reported cases of coronavirus disease 2019 (COVID-19) in children aged <18 years appear to be asymptomatic or mild ( 1 ). Less is known about severe COVID-19 illness requiring hospitalization in children. During March 1–July 25, 2020, 576 pediatric COVID-19 cases were reported to the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET), a population-based surveillance system that collects data on laboratory-confirmed COVID-19–associated hospitalizations in 14 states ( 2 , 3 ). Based on these data, the cumulative COVID-19-associated hospitalization rate among children aged <18 years during March 1–July 25, 2020, was 8.0 per 100,000 population, with the highest rate among children aged <2 years (24.8). During March 21–July 25, weekly hospitalization rates steadily increased among children (from 0.1 to 0.4 per 100,000, with a weekly high of 0.7 per 100,000). Overall, Hispanic or Latino (Hispanic) and non-Hispanic black (black) children had higher cumulative rates of COVID-19–associated hospitalizations (16.4 and 10.5 per 100,000, respectively) than did non-Hispanic white (white) children (2.1). Among 208 (36.1%) hospitalized children with complete medical chart reviews, 69 (33.2%) were admitted to an intensive care unit (ICU); 12 of 207 (5.8%) required invasive mechanical ventilation, and one patient died during hospitalization. Although the cumulative rate of pediatric COVID-19–associated hospitalization remains low (8.0 per 100,000 population) compared with that among adults (164.5),* weekly rates increased during the surveillance period, and one in three hospitalized children were admitted to the ICU, similar to the proportion among adults. Continued tracking of SARS-CoV-2 infections among children is important to characterize morbidity and mortality. Reinforcement of prevention efforts is essential in congregate settings that serve children, including childcare centers and schools. COVID-NET conducts population-based surveillance for laboratory-confirmed COVID-19–associated hospitalizations in 99 counties † in 14 states (California, Connecticut, Colorado, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah), representing all 10 U.S. Department of Health and Human Services regions ( 2 , 3 ). Laboratory-confirmed COVID-19–associated hospitalizations among residents in a predefined surveillance catchment area who had a positive SARS-CoV-2 molecular test during hospitalization or up to 14 days before admission are included in surveillance. SARS-CoV-2 tests are ordered at the discretion of the treating health care provider. Trained surveillance officers perform medical chart abstractions for all identified cases. Patients aged <18 years hospitalized with COVID-19 during March 1–July 25, 2020, were included in this analysis. Weekly and cumulative COVID-19–associated hospitalization rates were calculated using the number of catchment area residents hospitalized with COVID-19 as the numerator and the National Center for Health Statistics vintage 2019 bridged-race postcensal population estimates as the denominator. § Descriptive analyses were conducted using all available data; however, for clinical interventions, treatments, and outcomes, only those hospitalizations with complete medical chart review and a discharge disposition (i.e., discharged alive or died during hospitalization) were included. Obesity was defined as body mass index (kg/m2) ≥95th percentile for age and sex based on CDC growth charts among children aged ≥2 years; this was not evaluated for children <2 years. All analyses were conducted using SAS statistical software (version 9.4; SAS Institute). COVID-NET activities were determined by CDC to be public health surveillance. ¶ Participating sites obtained approval for COVID-NET surveillance from their respective state and local Institutional Review Boards, as required. During March 1–July 25, 576 children hospitalized with COVID-19 were reported to COVID-NET. Infants aged <3 months accounted for 18.8% of all children hospitalized with COVID-19 (Table). The median patient age was 8 years (interquartile range [IQR] = 9 months–15 years), and 292 (50.7%) were males. Among 526 (91.3%) children for whom race and ethnicity information were reported, 241 (45.8%) were Hispanic, 156 (29.7%) were black, 74 (14.1%) were white; 24 (4.6%) were non-Hispanic Asian or Pacific Islander; and four (0.8%) were non-Hispanic American Indian/Alaska Native. TABLE Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 — COVID-NET, 14 States,* March 1–July 25, 2020 † Characteristic No./Total no. (%) All ages 0–2 yrs 2–4 yrs 5–17 yrs Age (N = 576) 0–2 mos 108/576 (18.8) — — — 3–5 mos 20/576 (3.5) — — — 6–11 mos 29/576 (5.0) — — — 12–23 mos 31/576 (5.4) — — — 2–4 yrs 50/576 (8.7) — — — 5–11 yrs 97/576 (16.8) — — — 12–17 yrs 241/576 (41.8) — — — Age (N = 576) median (IQR) 8 yrs (9 mos–15 yrs) Sex (N = 576) Male 292/576 (50.7) 106/188 (56.4) 25/50 (50.0) 161/338 (47.6) Female 284/576 (49.3) 82/188 (43.6) 25/50 (50.0) 177/338 (52.4) Race/Ethnicity (N = 526) NH White 74/526 (14.1) 29/162 (17.9) 5/46 (10.9) 40/318 (12.6) NH Black 156/526 (29.7) 38/162 (23.5) 17/46 (37.0) 101/318 (31.8) Hispanic or Latino 241/526 (45.8) 73/162 (45.1) 18/46 (39.1) 150/318 (47.2) NH American Indian/Alaska Native 4/526 (0.8) 0/162 (—) 0/46 (—) 4/318 (1.3) NH Asian or Pacific Islander 24/526 (4.6) 13/162 (8.0) 3/46 (6.5) 8/318 (2.5) Multiple races 3/526 (0.6) 0/162 (—) 1/46 (2.2) 2/318 (0.6) Unknown 24/526 (4.6) 9/162 (5.6) 2/46 (4.3) 13/318 (4.1) Any underlying condition (N = 222) 94/222 (42.3) 14/65 (21.5) 9/24 (37.5) 71/133 (53.4) Obesity§ 42/111 (37.8) N/A 6/18 (33.3) 36/93 (38.7) Chronic lung disease 40/222 (18.0) 2/65 (3.1) 4/24 (16.7) 34/133 (25.6)   Asthma 30/222 (13.5) 1/65 (1.5) 0/24 (0) 29/133 (21.8) Prematurity (gestational age <37 weeks)¶ 10/65 (15.4) 10/65 (15.4) N/A N/A Neurologic disorder 31/222 (14.0) 6/65 (9.2) 7/24 (29.2) 18/133 (13.5) Immunocompromised condition 12/222 (5.4) 0/65 (—) 2/24 (8.3) 10/133 (7.5) Feeding tube dependent 12/222 (5.4) 4/65 (6.2) 3/24 (12.5) 5/133 (3.8) Chronic metabolic disease 10/222 (4.5) 1/65 (1.5) 0/24 (—) 9/133 (6.8)   Diabetes mellitus 6/222 (2.7) 0/65 (—) 0/24 (—) 6/133 (4.5) Blood disorders 8/222 (3.6) 0/65 (—) 0/24 (—) 8/133 (6.0)   Sickle cell disease 5/222 (2.3) 0/65 (—) 0/24 (—) 5/133 (3.8) Cardiovascular disease 7/222 (3.2) 2/65 (3.1) 2/24 (8.3) 3/133 (2.3)   Congenital heart disease 4/222 (1.8) 2/65 (3.1) 1/24 (4.2) 1/133 (0.8) Any underlying condition by race/ethnicity (N = 94) NH White 14/94 (14.9) 4/14 (28.6) 0/9 (—) 10/71 (14.1) NH Black 28/94 (29.8) 3/14 (21.4) 2/9 (22.2) 23/71 (32.4) Hispanic or Latino 43/94 (45.7) 7/14 (50) 6/9 (66.7) 30/71 (42.3) NH American Indian/Alaska Native 2/94 (2.1) 0/14 (—) 0/9 (—) 2/71 (2.8) NH Asian or Pacific Islander 3/94 (3.2) 0/14 (—) 0/9 (—) 3/71 (4.2) Multiracial 1/94 (1.1) 0/14 (—) 1/9 (11.1) 0/71 (—) Unknown 3/94 (3.2) 0/14 (—) 0/9 (—) 3/71 (4.2) Signs and symptoms (N = 224) Fever/chills 121/224 (54.0) 50/67 (74.6) 13/24 (54.2) 58/133 (43.6) Inability to eat/poor feeding¶ 22/67 (32.8) 22/67 (32.8) N/A N/A Nausea/vomiting 69/224 (30.8) 14/67 (20.9) 6/24 (25.0) 49/133 (36.8) Cough 66/224 (29.5) 17/67 (25.4) 3/24 (12.5) 46/133 (34.6) Nasal congestion/rhinorrhea 53/224 (23.7) 22/67 (32.8) 5/24 (20.8) 26/133 (19.5) Shortness of breath/respiratory distress 50/224 (22.3) 9/67 (13.4) 2/24 (8.3) 39/133 (29.3) Abdominal pain 42/224 (18.8) 2/67 (3.0) 3/24 (12.5) 37/133 (27.8) Diarrhea 27/224 (12.1) 5/67 (7.5) 3/24 (12.5) 19/133 (14.3) Hospitalization length of stay (N = 208) median days (IQR) 2.5 (1—5) 2 (1—2) 3 (1—4) 3 (2—6) Chest radiograph findings (N = 67) Infiltrate/consolidation 44/67 (65.7) 8/15 (53.3) 3/9 (33.3) 33/43 (76.7) Bronchopneumonia/pneumonia 14/67 (20.9) 2/15 (13.3) 0/9 (—) 12/43 (27.9) Pleural effusion 4/67 (6.0) 0/15 (—) 1/9 (11.1) 3/43 (7.0) Chest CT findings (N = 14) Ground glass opacities 10/14 (71.4) 1/1 (100.0) 1/1 (100.0) 8/12 (66.7) Infiltrate/consolidation 7/14 (50.0) 0/1 (—) 0/1 (—) 7/12 (58.3) Bronchopneumonia/pneumonia 4/14 (28.6) 0/1 (—) 0/1 (—) 4/12 (33.3) Pleural effusion 3/14 (21.4) 0/1 (—) 0/1 (—) 3/12 (25.0) COVID-19 investigational treatment (N = 208)** Received treatment 12/208 (5.8) 0/61 (—) 0/24 (—) 12/123 (9.8)   Remdesivir 9/208 (4.3) 0/61 (—) 0/24 (—) 9/123 (7.3)   Azithromycin†† 6/208 (2.9) 0/61 (—) 0/24 (—) 6/123 (4.9)   Hydroxychloroquine 4/208 (1.9) 0/61 (—) 0/24 (—) 4/123 (3.3)   Convalescent plasma 1/208 (0.5) 0/61 (—) 0/24 (—) 1/123 (0.8)   Lopinavir-ritonavir§§ 1/208 (0.5) 0/61 (—) 0/24 (—) 1/123 (0.8) ICU admission (N = 208) 69/208 (33.2) 19/61 (31.1) 9/24 (37.5) 41/123 (33.3) ICU length of stay median days (IQR) 2 (1—5) 1 (1—3) 2 (2—5) 3.5 (1—7) Interventions (N = 208) ¶¶ Invasive mechanical ventilation*** 12/207 (5.8) 0/61 (—) 4/24 (16.7) 8/122 (6.6) BIPAP/CPAP*** 8/207 (3.9) 2/61 (3.3) 2/24 (8.3) 4/122 (3.3) High flow nasal cannula*** 5/207 (2.4) 1/61 (1.6) 1/24 (4.2) 3/122 (2.5) Systemic steroids 19/208 (9.1) 1/61 (1.6) 4/24(16.7) 14/123 (11.4) IVIG 14/208 (6.7) 1/61 (1.6) 5/24 (20.8) 8/123 (6.5) Vasopressor 10/208 (4.8) 0/61 (—) 0/24 (—) 10/123 (8.1) New clinical discharge diagnoses (N = 208) Pneumonia 23/208 (11.1) 2/61 (3.3) 2/24 (8.3) 19/123 (15.4) Multisystem inflammatory syndrome in children (MIS-C)††† 9/83 (10.8) 1/15 (6.7) 5/15 (33.3) 3/53 (5.7) Acute respiratory failure 10/208 (4.8) 0/61 (—) 3/24 (12.5) 7/123 (5.7) Acute kidney injury 6/208 (2.9) 0/61 (—) 0/24 (—) 6/123 (4.9) Diabetic ketoacidosis 6/208 (2.9) 0/61 (—) 0/24 (—) 6/123 (4.9) Acute respiratory distress syndrome 4/208 (1.9) 1/61 (1.6) 0/24 (—) 3/123 (2.4) Died during hospitalization (N = 208) 1/208 (0.5) 0/61 (—) 0/24 (—) 1/123 (0.8) Abbreviations: BIPAP = bilevel positive airway pressure; CT = computed tomography; CPAP = continuous positive airway pressure; COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network; ICU = intensive care unit; IQR = interquartile range; IVIG = intravenous immune globulin; N/A = not applicable; NH = non-Hispanic. * California, Connecticut, Colorado, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah. † Analyses were conducted on all available data; however, for hospitalization length of stay, radiology findings, treatments, ICU admission, interventions, new clinical diagnoses, and outcome, only cases with a complete medical chart review and a discharge disposition (i.e. discharged alive or died during hospitalization) were included. § Obesity was defined as body mass index (kg/m2) ≥95th percentile for age and sex based on CDC growth charts among children aged ≥2 years; this was not evaluated for children <2 years. ¶ Data collected only on children aged <2 years. ** Not mutually exclusive treatment categories. †† Given with at least one other COVID-19 investigational treatment. §§ Not given for human immunodeficiency virus infection. ¶¶ Two hospitalized children received extracorporeal membrane oxygenation (1 each aged <2 years and 5–17 years). None received renal replacement therapy. *** Highest level of respiratory support for each case that needed respiratory support. ††† Since June 18, a discharge diagnosis of multisystem inflammatory syndrome in children (MIS-C) was systematically collected through COVID-NET. The cumulative COVID-19–associated hospitalization rate among children aged <18 years during the surveillance period was 8.0 per 100,000 and was highest among children aged <2 years (24.8); rates were substantially lower in children aged 2–4 years (4.2) and 5–17 years (6.4) (Figure 1). Overall weekly hospitalization rates among children increased steadily during the surveillance period (from 0.1 to 0.4 per 100,000, with a weekly high of 0.7 per 100,000; trend test, p<0.001) (Figure 1). COVID-19–associated hospitalization rates were higher among Hispanic and black children than among white children (Figure 2); the rates among Hispanic and black children were nearly eight times and five times, respectively, the rate in white children. FIGURE 1 Cumulative (A) and weekly (B) COVID-19–associated hospitalization rates * ,† among children aged <18 years, by age group — COVID-NET, 14 states § , March 1–July 25, 2020 ¶ Abbreviation: COVID-NET = Coronavirus Disease 2019–Associated Hospitalization Surveillance Network. * Number of children in each age group hospitalized with COVID-19 per 100,000 population. † Figure B shows the 3-week moving average of weekly hospitalization rates for children in each age group hospitalized with COVID-19 per 100,000 population. A trend test was conducted using weighted linear regression, where the weight for each week was the inverse of the variance. Trend test overall (<18 years): p-value <0.001. § Counties included in COVID-NET surveillance: California (Alameda, Contra Costa, and San Francisco counties); Colorado (Adams, Arapahoe, Denver, Douglas, and Jefferson counties); Connecticut (New Haven and Middlesex counties); Georgia (Clayton, Cobb, DeKalb, Douglas, Fulton, Gwinnett, Newton, and Rockdale counties); Iowa (one county represented); Maryland (Allegany, Anne Arundel, Baltimore, Baltimore City, Calvert, Caroline, Carroll, Cecil, Charles, Dorchester, Frederick, Garrett, Harford, Howard, Kent, Montgomery, Prince George’s, Queen Anne’s, St. Mary’s, Somerset, Talbot, Washington, Wicomico, and Worcester counties); Michigan (Clinton, Eaton, Genesee, Ingham, and Washtenaw counties); Minnesota (Anoka, Carver, Dakota, Hennepin, Ramsey, Scott, and Washington counties); New Mexico (Bernalillo, Chaves, Dona Ana, Grant, Luna, San Juan, and Santa Fe counties); New York (Albany, Columbia, Genesee, Greene, Livingston, Monroe, Montgomery, Ontario, Orleans, Rensselaer, Saratoga, Schenectady, Schoharie, Wayne, and Yates counties); Ohio (Delaware, Fairfield, Franklin, Hocking, Licking, Madison, Morrow, Perry, Pickaway, and Union counties); Oregon (Clackamas, Multnomah, and Washington counties); Tennessee (Cheatham, Davidson, Dickson, Robertson, Rutherford, Sumner, Williamson, and Wilson counties); and Utah (Salt Lake County). ¶ Data are preliminary, and case counts and rates for recent hospital admissions are subject to lag. As data are received each week, previous case counts and rates are updated accordingly. The figure is a line graph consisting of two sections showing the cumulative and weekly COVID-19–associated hospitalization rates among U.S. children aged <18 years, by age group in the 14 states participating in the Coronavirus Disease 2019–Associated Hospitalization Surveillance Network. FIGURE 2 Cumulative COVID-19–associated hospitalization rates* among children aged <18 years, by age group and race/ethnicity — COVID-NET, 14 states † , March 1–July 25, 2020 § , ¶ Abbreviation: COVID-NET = Coronavirus Disease 2019–Associated Hospitalization Surveillance Network. * Number of children aged <18 years hospitalized with COVID-19 per 100,000 population. † Counties included in COVID-NET surveillance: California (Alameda, Contra Costa, and San Francisco counties); Colorado (Adams, Arapahoe, Denver, Douglas, and Jefferson counties); Connecticut (New Haven and Middlesex counties); Georgia (Clayton, Cobb, DeKalb, Douglas, Fulton, Gwinnett, Newton, and Rockdale counties); Iowa (one county represented); Maryland (Allegany, Anne Arundel, Baltimore, Baltimore City, Calvert, Caroline, Carroll, Cecil, Charles, Dorchester, Frederick, Garrett, Harford, Howard, Kent, Montgomery, Prince George’s, Queen Anne’s, St. Mary’s, Somerset, Talbot, Washington, Wicomico, and Worcester counties); Michigan (Clinton, Eaton, Genesee, Ingham, and Washtenaw counties); Minnesota (Anoka, Carver, Dakota, Hennepin, Ramsey, Scott, and Washington counties); New Mexico (Bernalillo, Chaves, Dona Ana, Grant, Luna, San Juan, and Santa Fe counties); New York (Albany, Columbia, Genesee, Greene, Livingston, Monroe, Montgomery, Ontario, Orleans, Rensselaer, Saratoga, Schenectady, Schoharie, Wayne, and Yates counties); Ohio (Delaware, Fairfield, Franklin, Hocking, Licking, Madison, Morrow, Perry, Pickaway, and Union counties); Oregon (Clackamas, Multnomah, and Washington counties); Tennessee (Cheatham, Davidson, Dickson, Robertson, Rutherford, Sumner, Williamson, and Wilson counties); and Utah (Salt Lake County). § Data are preliminary, and case counts and rates for recent hospital admissions are subject to lag. As data are received each week, prior case counts and rates are updated accordingly. As of July 25, 2020, 50 (8.7%) of 576 pediatric hospitalized cases were missing data on race and ethnicity. ¶ Rates are not shown among non-Hispanic Asian or Pacific Islanders and non-Hispanic American Indian/Alaska Natives because of small case counts, leading to unstable estimates. All non-Hispanic American Indian/Alaska Native hospitalized children were aged 5–17 years. The figure is a bar chart showing the cumulative COVID-19–associated hospitalization rates among U.S. children aged <18 years during March 1–July 25, 2020, by age group and race/ethnicity in the 14 states participating in the Coronavirus Disease 2019–Associated Hospitalization Surveillance Network. Among 222 (38.5%) of 576 children with information on underlying medical conditions, 94 (42.3%) had one or more underlying conditions (Table). The most prevalent conditions included obesity (37.8%), chronic lung disease (18.0%), and prematurity (gestational age <37 weeks at birth, collected only for children aged <2 years) (15.4%). Hispanic and black children had higher prevalences of underlying conditions (45.7% and 29.8%, respectively) compared with white children (14.9%). Reported signs and symptoms upon hospital admission differed by age: fever or chills were the most common sign and symptom overall (54%) and were most prevalent among children aged <2 years (74.6%). Gastrointestinal symptoms, including nausea or vomiting, abdominal pain, or diarrhea, were reported by 42% of hospitalized children overall. A medical chart review was completed for 208 (36.1%) children. Median duration of hospitalization was 2.5 days (IQR = 1–5 days). Among 67 children who had a chest radiograph during hospitalization, 44 (65.7%) radiographs showed an infiltrate or consolidation. Among 14 children with chest computed tomography results available, ground-glass opacities (a nonspecific sign indicating infection or alveolar disease) was reported in 10. COVID-19 investigational treatments were only administered to 12 (5.8%) children, all aged 5–17 years; nine received remdesivir. Intravenous immunoglobulin was received by 14 of 208 (6.7%) children. Sixty-nine children (33.2%) were admitted to the ICU for a median of 2 days (IQR = 1–5 days). Invasive mechanical ventilation was required by 12 (5.8%) of 207 children. Since June 18, a discharge diagnosis of multisystem inflammatory syndrome in children (MIS-C) has been systematically collected**; overall, nine (10.8%) of 83 children with completed chart reviews for whom information about MIS-C was systematically collected received a diagnosis of MIS-C. Among 208 children with a discharge disposition, one child (0.5%) with multiple underlying conditions died during hospitalization. Discussion Since March 1, 2020, COVID-NET has identified 576 pediatric COVID-19–associated hospitalizations. Although the cumulative COVID-19–associated hospitalization rate among children is low compared with that among adults, weekly hospitalization rates in children increased during the surveillance period. Children can develop severe COVID-19 illness; during the surveillance period, one in three children were admitted to the ICU. Hispanic and black children had the highest rates of COVID-19–associated hospitalization. Continued surveillance will allow for further characterization of the burden and outcomes of COVID-19–associated hospitalizations among children. These data will help to better define the clinical spectrum of disease in children and the contributions of race and ethnicity and underlying medical conditions to hospitalizations and outcomes. Reasons for disparities in COVID-19-associated hospitalization rates by race and ethnicity are not fully understood. This report found the highest rates of COVID-19-associated hospitalization among Hispanic children. Similarly, a recent study from the Baltimore-District of Columbia region found a higher prevalence of SARS-CoV-2 infection in the Hispanic community compared with that in other racial and ethnic communities ( 4 ). Although hospitalization rates were lower for Hispanic persons than for black and white persons, hospitalized Hispanic patients were more likely to be younger (aged <44 years) ( 4 ). It has been hypothesized that Hispanic adults might be at increased risk for SARS-CoV-2 infection because they are overrepresented in frontline (e.g., essential and direct-service) occupations with decreased opportunities for social distancing, which might also affect children living in those households ( 4 ). During the 2009 influenza A H1N1 pandemic, pediatric mortality rates also were higher among underrepresented ethnic groups in a study from England ( 5 ). Forty-two percent of children in this analysis had one or more underlying medical conditions, with higher prevalences among Hispanic and black children. This suggests that the presence of underlying conditions place children at higher risk for COVID-19-associated hospitalizations and that observed disparities might in part be related to the higher prevalence of underlying conditions among hospitalized Hispanic and black children compared with those among white children. This study, along with other studies of hospitalized children with COVID-19, found that obesity was the most prevalent underlying medical condition ( 6 , 7 ). Childhood obesity affects almost one in five U.S. children and is more prevalent in black and Hispanic children ( 8 ); therefore, understanding the underlying pathophysiologic association between obesity and SARS-CoV-2 infection is important to identifying possible clinical interventions and preventive strategies to reduce the risk for hospitalization. This report and others have found that, although one third of children hospitalized with COVID-19 were admitted to the ICU, the case-fatality rate remains low, even among children hospitalized with more severe COVID-19–associated complications, such as MIS-C ( 6 , 7 , 9 ). By comparison, among U.S. children hospitalized with seasonal influenza virus infection, estimates of ICU admissions have ranged from 16% to 25% among hospitalized children without and with underlying medical conditions, respectively, and reports of in-hospital deaths also are rare (<1%) ( 10 ). The percentage of ICU admission was similar among children (33.2%) and adults (32.0%) reported to COVID-NET; however, invasive mechanical ventilation was required less frequently in children (5.8%) than in adults (18.6%) ( 3 ). Continued monitoring of hospitalizations, ICU admissions, and mortality among children is important to understand potential risk factors for severe outcomes. The findings in this report are subject to at least five limitations. First, laboratory confirmation is dependent on clinician-ordered SARS-CoV-2 molecular testing. Rates likely are underestimates; cases can be missed because of test availability, test performance, and provider or facility testing practices. Second, hospitalization rates by age group and race/ethnicity are preliminary and might change as additional cases are identified during the surveillance period. Third, analysis of interventions, treatments, and outcomes was based on a convenience sample of children with a final disposition and complete chart reviews. A higher proportion of included children were aged <6 months, and two sites contributed more than half of cases; however, compared with other single-center or state-based studies, COVID-NET is more geographically and racially diverse ( 2 ). Approximately 60% of pediatric hospitalizations reported to COVID-NET have not had a chart review, and this sample might be biased. In the future, COVID-NET plans to have complete, population-based data on hospitalized children. Finally, COVID-NET did not systematically collect information on MIS-C until June 18. In addition, given that molecular tests can miss approximately half of patients with MIS-C despite serologic or epidemiologic evidence of a past SARS-CoV-2 infection ( 9 ), COVID-NET surveillance likely underestimates the percentage of MIS-C cases among SARS-CoV-2 infections in children. Using a multisite, geographically diverse network, this report found that children with SARS-CoV-2 infection can have severe illness requiring hospitalization and intensive care. Improved understanding of the social determinants of health is needed to inform and reduce disparities as evidenced by pediatric COVID-19-associated hospitalization rates. Similar to the general population, children should be encouraged to wash their hands often and continue social distancing, and children aged ≥2 years should wear a mask when around persons outside of their families to reduce the risk for SARS-CoV-2 infection and transmission to others. Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children. Summary What is already known about this topic? Most reported SARS-CoV-2 infections in children aged <18 years are asymptomatic or mild. Less is known about severe COVID-19 in children requiring hospitalization. What is added by this report? Analysis of pediatric COVID-19 hospitalization data from 14 states found that although the cumulative rate of COVID-19–associated hospitalization among children (8.0 per 100,000 population) is low compared with that in adults (164.5), one in three hospitalized children was admitted to an intensive care unit. What are the implications for public health practice? Children are at risk for severe COVID-19. Public health authorities and clinicians should continue to track pediatric SARS-CoV-2 infections. Reinforcement of prevention efforts is essential in congregate settings that serve children, including childcare centers and schools.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020

              As of October 15, 216,025 deaths from coronavirus disease 2019 (COVID-19) have been reported in the United States*; however, this number might underestimate the total impact of the pandemic on mortality. Measures of excess deaths have been used to estimate the impact of public health pandemics or disasters, particularly when there are questions about underascertainment of deaths directly attributable to a given event or cause ( 1 – 6 ). † Excess deaths are defined as the number of persons who have died from all causes, in excess of the expected number of deaths for a given place and time. This report describes trends and demographic patterns in excess deaths during January 26–October 3, 2020. Expected numbers of deaths were estimated using overdispersed Poisson regression models with spline terms to account for seasonal patterns, using provisional mortality data from CDC’s National Vital Statistics System (NVSS) ( 7 ). Weekly numbers of deaths by age group and race/ethnicity were assessed to examine the difference between the weekly number of deaths occurring in 2020 and the average number occurring in the same week during 2015–2019 and the percentage change in 2020. Overall, an estimated 299,028 excess deaths have occurred in the United States from late January through October 3, 2020, with two thirds of these attributed to COVID-19. The largest percentage increases were seen among adults aged 25–44 years and among Hispanic or Latino (Hispanic) persons. These results provide information about the degree to which COVID-19 deaths might be underascertained and inform efforts to prevent mortality directly or indirectly associated with the COVID-19 pandemic, such as efforts to minimize disruptions to health care. Estimates of excess deaths can provide a comprehensive account of mortality related to the COVID-19 pandemic, including deaths that are directly or indirectly attributable to COVID-19. Estimates of the numbers of deaths directly attributable to COVID-19 might be limited by factors such as the availability and use of diagnostic testing (including postmortem testing) and the accurate and complete reporting of cause of death information on the death certificate. Excess death analyses are not subject to these limitations because they examine historical trends in all-cause mortality to determine the degree to which observed numbers of deaths differ from historical norms. In April 2020, CDC’s National Center for Health Statistics (NCHS) began publishing data on excess deaths associated with the COVID-19 pandemic ( 7 , 8 ). This report describes trends and demographic patterns in the number of excess deaths occurring in the United States from January 26, 2020, through October 3, 2020, and differences by age and race/ethnicity using provisional mortality data from the NVSS. § Excess deaths are typically defined as the number of persons who have died from all causes, in excess of the expected number of deaths for a given place and time. A detailed description of the methodology for estimating excess deaths has been described previously ( 7 ). Briefly, expected numbers of deaths are estimated using overdispersed Poisson regression models with spline terms to account for seasonal patterns. The average expected number, as well as the upper bound of the 95% prediction interval (the range of values likely to contain the value of a single new observation), are used as thresholds to determine the number of excess deaths (i.e., observed numbers above each threshold) and percentage excess (excess deaths divided by average expected number of deaths). Estimates described here refer to the number or percentage above the average; estimates above the upper bound threshold have been published elsewhere ( 7 ). Observed numbers of deaths are weighted to account for incomplete reporting by jurisdictions (50 states and the District of Columbia [DC]) in the most recent weeks, where the weights were estimated based on completeness of provisional data in the past year ( 7 ). Weekly NVSS data on excess deaths occurring from January 26 (the week ending February 1), 2020, through October 3, 2020, were used to quantify the number of excess deaths and the percentage excess for deaths from all causes and deaths from all causes excluding COVID-19. ¶ Deaths attributed to COVID-19 have the International Classification of Diseases, Tenth Revision code U07.1 as an underlying or contributing cause of death. Weekly numbers of deaths by age group (0–24, 25–44, 45–64, 65–74, 75–84, and ≥85 years) and race/ethnicity (Hispanic or Latino [Hispanic], non-Hispanic White [White], non-Hispanic Black or African American [Black], non-Hispanic Asian [Asian], non-Hispanic American Indian or Alaska Native [AI/AN], and other/unknown race/ethnicity, which included non-Hispanic Native Hawaiian or other Pacific Islander, non-Hispanic multiracial, and unknown) were used to examine the difference between the weekly number of deaths occurring in 2020 and the average number occurring in the same week during 2015–2019. These values were used to calculate an average percentage change in 2020 (i.e., above or below average compared with past years), over the period of analysis, by age group and race and Hispanic ethnicity. NVSS data in this report include all deaths occurring in the 50 states and DC and are not limited to U.S. residents. Approximately 0.2% of decedents overall are foreign residents. R statistical software (version 3.5.0; The R Foundation) was used to conduct all analyses. From January 26, 2020, through October 3, 2020, an estimated 299,028 more persons than expected have died in the United States.** Excess deaths reached their highest points to date during the weeks ending April 11 (40.4% excess) and August 8, 2020 (23.5% excess) (Figure 1). Two thirds of excess deaths during the analysis period (66.2%; 198,081) were attributed to COVID-19 and the remaining third to other causes †† (Figure 1). FIGURE 1 Weekly numbers of deaths from all causes and from all causes excluding COVID-19 relative to the average expected number and the upper bound of the 95% prediction interval (A), and the weekly and total numbers of deaths from all causes and from all causes excluding COVID-19 above the average expected number and the upper bound of the 95% prediction interval (B) — National Vital Statistics System, United States, January–September 2020 Abbreviation: COVID-19 = coronavirus disease 2019. The figure is a histogram, an epidemiologic curve showing the weekly numbers of deaths from all causes and from all causes excluding COVID-19 relative to the average expected number and the upper bound of the 95% prediction interval (A), and the weekly and total numbers of deaths from all causes and from all causes excluding COVID-19 above the average expected number and the upper bound of the 95% prediction interval (B), using data from the National Vital Statistics System, in United States, during January–September 2020. The total number of excess deaths (deaths above average levels) from January 26 through October 3 ranged from a low of approximately 841 in the youngest age group (<25 years) to a high of 94,646 among adults aged 75–84 years. §§ However, the average percentage change in deaths over this period compared with previous years was largest for adults aged 25–44 years (26.5%) (Figure 2). Overall, numbers of deaths among persons aged <25 years were 2.0% below average, ¶¶ and among adults aged 45–64, 65–74 years, 75–84, and ≥85 years were 14.4%, 24.1%, 21.5%, and 14.7% above average, respectively. FIGURE 2 Percentage change in the weekly number of deaths in 2020 relative to average numbers in the same weeks during 2015–2019, by age group — United States, 2015–2019 and 2020 The figure is a histogram, an epidemiologic curve showing the percentage change in the weekly number of deaths in 2020 relative to average numbers during the same weeks in 2015–2019, by age group, in the United States, during 2015–2019 and 2020. When examined by race and ethnicity, the total numbers of excess deaths during the analysis period ranged from a low of approximately 3,412 among AI/AN persons to a high of 171,491 among White persons. For White persons, deaths were 11.9% higher when compared to average numbers during 2015–2019. However, some racial and ethnic subgroups experienced disproportionately higher percentage increases in deaths (Figure 3). Specifically, the average percentage increase over this period was largest for Hispanic persons (53.6%). Deaths were 28.9% above average for AI/AN persons, 32.9% above average for Black persons, 34.6% above average for those of other or unknown race or ethnicity, and 36.6% above average for Asian persons. FIGURE 3 Percentage change in the weekly number of deaths in 2020 relative to average numbers in the same weeks during 2015–2019, by race and Hispanic ethnicity — United States, 2015–2019 and 2020 The figure is a histogram, an epidemiologic curve showing the percentage change in the weekly number of deaths in 2020 relative to average numbers in the same weeks during 2015–2019, by race and Hispanic ethnicity, in the United States, during 2015–2019 and 2020. Discussion Based on NVSS data, excess deaths have occurred every week in the United States since March 2020. An estimated 299,028 more persons than expected have died since January 26, 2020; approximately two thirds of these deaths were attributed to COVID-19. A recent analysis of excess deaths from March through July reported very similar findings, but that study did not include more recent data through September ( 5 ). Although more excess deaths have occurred among older age groups, relative to past years, adults aged 25–44 years have experienced the largest average percentage increase in the number of deaths from all causes from late January through October 3, 2020. The age distribution of COVID-19 deaths shifted toward younger age groups from May through August ( 9 ); however, these disproportionate increases might also be related to underlying trends in other causes of death. Future analyses might shed light on the extent to which increases among younger age groups are driven by COVID-19 or by other causes of death. Among racial and ethnic groups, the smallest average percentage increase in numbers of deaths compared with previous years occurred among White persons (11.9%) and the largest for Hispanic persons (53.6%), with intermediate increases (28.9%–36.6%) among AI/AN, Black, and Asian persons. These disproportionate increases among certain racial and ethnic groups are consistent with noted disparities in COVID-19 mortality.*** The findings in this report are subject to at least five limitations. First, the weighting of provisional NVSS mortality data might not fully account for reporting lags, particularly in recent weeks. Estimated numbers of deaths in the most recent weeks are likely underestimated and will increase as more data become available. Second, there is uncertainty associated with the models used to generate the expected numbers of deaths in a given week. A range of values for excess death estimates is provided elsewhere ( 7 ), but these ranges might not reflect all of the sources of uncertainty, such as the completeness of provisional data. Third, different methods or models for estimating the expected numbers of deaths might lead to different results. Estimates of the number or percentage of deaths above average levels by race/ethnicity and age reported here might not sum to the total numbers of excess deaths reported elsewhere, which might have been estimated using different methodologies. Fourth, using the average numbers of deaths from past years might underestimate the total expected numbers because of population growth or aging, or because of increasing trends in certain causes such as drug overdose mortality. Finally, estimates of excess deaths attributed to COVID-19 might underestimate the actual number directly attributable to COVID-19, because deaths from other causes might represent misclassified COVID-19–related deaths or deaths indirectly caused by the pandemic. Specifically, deaths from circulatory diseases, Alzheimer disease and dementia, and respiratory diseases have increased in 2020 relative to past years ( 7 ), and it is unclear to what extent these represent misclassified COVID-19 deaths or deaths indirectly related to the pandemic (e.g., because of disruptions in health care access or utilization). Despite these limitations, however, this report demonstrates important trends and demographic patterns in excess deaths that occurred during the COVID-19 pandemic. These results provide more information about deaths during the COVID-19 pandemic and inform public health messaging and mitigation efforts focused on the prevention of infection and mortality directly or indirectly associated with the COVID-19 pandemic and the elimination of health inequities. CDC continues to recommend the use of masks, frequent handwashing, and maintenance of social distancing to prevent COVID-19. ††† Summary What is already known about this topic? As of October 15, 216,025 deaths from COVID-19 have been reported in the United States; however, this might underestimate the total impact of the pandemic on mortality. What is added by this report? Overall, an estimated 299,028 excess deaths occurred from late January through October 3, 2020, with 198,081 (66%) excess deaths attributed to COVID-19. The largest percentage increases were seen among adults aged 25–44 years and among Hispanic or Latino persons. What are the implications for public health practice? These results inform efforts to prevent mortality directly or indirectly associated with the COVID-19 pandemic, such as efforts to minimize disruptions to health care.
                Bookmark

                Author and article information

                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb Mortal Wkly Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                19 March 2021
                19 March 2021
                : 70
                : 11
                : 382-388
                Affiliations
                Epidemic Intelligence Service, CDC; CDC COVID-19 Response Team; New Mexico Department of Health; Hawaii State Department of Health; Office of Minority Health and Health Equity, CDC.
                Author notes
                Corresponding author: Miriam Van Dyke, mpy4@ 123456cdc.gov .
                Article
                mm7011e1
                10.15585/mmwr.mm7011e1
                7976617
                33735165
                1828bcb4-eee2-4c82-b829-65e303abf734

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article